$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000157628023000060 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$137.2M	$128.7M	$126.9M
YoY Change	25.66%	33.94%	17.37%
Cost Of Revenue	$53.85M	$53.07M	$47.12M
YoY Change	46.62%	65.95%	40.99%
Gross Profit	$83.30M	$75.64M	$79.77M
YoY Change	15.03%	17.97%	6.81%
Gross Profit Margin	60.74%	58.77%	62.86%
Selling, General & Admin	$112.6M	$116.6M	$119.3M
YoY Change	-4.03%	10.28%	19.46%
% of Gross Profit	135.12%	154.11%	149.57%
Research & Development	$90.36M	$93.13M	$106.6M
YoY Change	5.74%	13.91%	45.96%
% of Gross Profit	108.47%	123.12%	133.61%
Depreciation & Amortization	$10.63M	$10.35M	$10.17M
YoY Change	31.25%	43.66%	66.98%
% of Gross Profit	12.76%	13.68%	12.75%
Operating Expenses	$202.9M	$209.7M	$225.9M
YoY Change	0.09%	11.86%	30.65%
Operating Profit	-$119.6M	-$134.1M	-$146.1M
YoY Change	-8.21%	8.69%	48.79%
Interest Expense	$70.08M	$644.0K	$6.906M
YoY Change	10765.43%	0.0%	68960.0%
% of Operating Profit
Other Income/Expense, Net	$859.0K	-$1.654M	-$119.0K
YoY Change	127.25%	3345.83%	-113.25%
Pretax Income	-$72.28M	-$133.3M	-$139.3M
YoY Change	-68.44%	8.15%	92.71%
Income Tax	$496.0K	$240.0K	$602.0K
% Of Pretax Income
Net Earnings	-$72.77M	-$133.5M	-$139.9M
YoY Change	-68.28%	8.36%	53.92%
Net Earnings / Revenue	-53.06%	-103.74%	-110.28%
Basic Earnings Per Share	-$0.67	-$1.30
Diluted Earnings Per Share	-$0.67	-$1.30	-$1.37
COMMON SHARES
Basic Shares Outstanding	102.8M shares	102.7M shares	102.4M shares
Diluted Shares Outstanding	108.8M shares	102.7M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.225B	$937.0M	$1.011B
YoY Change	43.48%	-2.62%	8.41%
Cash & Equivalents	$271.1M	$223.6M	$141.6M
Short-Term Investments	$953.8M	$713.4M	$869.6M
Other Short-Term Assets	$25.81M	$33.76M	$31.51M
YoY Change	-8.75%	12.28%	-40.61%
Inventory	$60.53M	$46.47M	$51.60M
Prepaid Expenses
Receivables	$86.47M	$87.20M	$97.26M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.398B	$1.104B	$1.192B
YoY Change	34.76%	-0.79%	6.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$321.0M	$163.2M	$167.9M
YoY Change	96.5%	7.87%	34.92%
Goodwill	$3.290M	$3.290M	$3.290M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$10.36M	$11.05M	$11.73M
YoY Change	-20.96%	-19.52%	-17.46%
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$107.7M	$58.95M	$61.45M
YoY Change	52.63%	-16.87%	0.85%
Total Long-Term Assets	$442.4M	$407.2M	$418.4M
YoY Change	-45.83%	-59.94%	-61.63%
TOTAL ASSETS
Total Short-Term Assets	$1.398B	$1.104B	$1.192B
Total Long-Term Assets	$442.4M	$407.2M	$418.4M
Total Assets	$1.840B	$1.512B	$1.610B
YoY Change	-0.74%	-29.02%	-26.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$79.78M	$67.32M	$68.91M
YoY Change	115.8%	108.87%	291.99%
Accrued Expenses	$108.9M	$190.5M	$106.9M
YoY Change	41.16%	267.46%	136.07%
Deferred Revenue	$12.24M	$13.62M	$17.40M
YoY Change	-18.17%	28.86%	53.66%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$200.9M	$204.2M	$193.2M
YoY Change	19.78%	-10.77%	-0.75%
LONG-TERM LIABILITIES
Long-Term Debt	$1.139B	$1.138B	$1.137B
YoY Change	0.23%	0.23%	0.23%
Other Long-Term Liabilities	$207.7M	$9.136M	$9.179M
YoY Change	2136.24%	32.23%	133.38%
Total Long-Term Liabilities	$1.346B	$9.136M	$9.179M
YoY Change	14397.23%	32.23%	133.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$200.9M	$204.2M	$193.2M
Total Long-Term Liabilities	$1.346B	$9.136M	$9.179M
Total Liabilities	$1.547B	$1.556B	$1.550B
YoY Change	0.82%	-2.53%	-0.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.869B	-$1.796B	-$1.662B
YoY Change	37.36%	58.79%	64.95%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$292.7M	-$44.55M	$60.18M
YoY Change
Total Liabilities & Shareholders Equity	$1.840B	$1.512B	$1.610B
YoY Change	-0.74%	-29.02%	-26.97%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$72.77M	-$133.5M	-$139.9M
YoY Change	-68.28%	8.36%	53.92%
Depreciation, Depletion And Amortization	$10.63M	$10.35M	$10.17M
YoY Change	31.25%	43.66%	66.98%
Cash From Operating Activities	-$94.01M	-$74.44M	-$90.75M
YoY Change	-16.01%	160.11%	17.87%
INVESTING ACTIVITIES
Capital Expenditures	$6.513M	$7.524M	$10.00M
YoY Change	-128.28%	-66.85%	-140.61%
Acquisitions
YoY Change
Other Investing Activities	-$234.6M	$164.7M	$80.63M
YoY Change	370.55%	23.4%	-133.31%
Cash From Investing Activities	-$241.1M	$157.2M	$70.63M
YoY Change	230.8%	41.89%	-126.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	383.9M	-$854.0K	2.318M
YoY Change	-323.06%	7016.67%	-38.68%
NET CHANGE
Cash From Operating Activities	-94.01M	-$74.44M	-90.75M
Cash From Investing Activities	-241.1M	$157.2M	70.63M
Cash From Financing Activities	383.9M	-$854.0K	2.318M
Net Change In Cash	48.71M	$81.77M	-17.80M
YoY Change	-113.65%	0.47%	-94.76%
FREE CASH FLOW
Cash From Operating Activities	-$94.01M	-$74.44M	-$90.75M
Capital Expenditures	$6.513M	$7.524M	$10.00M
Free Cash Flow	-$100.5M	-$81.97M	-$100.8M
YoY Change	13.08%	59.72%	92.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38683
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3100 Hanover Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94304
CY2023Q1	dei	City Area Code CityAreaCode	855
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	698-8887
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	GH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	102764840	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	223640000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141647000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	713380000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	869584000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87204000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	97256000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	46474000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	51598000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33762000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31509000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1104460000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1191594000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163229000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	167920000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	170651000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	174001000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11047000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11727000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	58954000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61453000	usd
CY2023Q1	us-gaap	Assets Assets	1511631000	usd
CY2022Q4	us-gaap	Assets Assets	1609985000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	190534000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	175817000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13621000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	17403000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	204155000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	193220000	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1138034000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1137391000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	204857000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	210015000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9136000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9179000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1556182000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1549805000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102708305	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102708305	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102619383	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102619383	shares
CY2023Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1763544000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1742114000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12150000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19522000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1795946000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1662413000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-44551000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	60180000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1511631000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1609985000	usd
CY2023Q1	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	113393000	usd
CY2022Q1	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	84136000	usd
CY2023Q1	gh	Revenue From Development Services RevenueFromDevelopmentServices	15321000	usd
CY2022Q1	gh	Revenue From Development Services RevenueFromDevelopmentServices	11963000	usd
CY2023Q1	us-gaap	Revenues Revenues	128714000	usd
CY2022Q1	us-gaap	Revenues Revenues	96099000	usd
CY2023Q1	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	45106000	usd
CY2022Q1	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	30684000	usd
CY2023Q1	gh	Cost Of Development Services CostOfDevelopmentServices	7967000	usd
CY2022Q1	gh	Cost Of Development Services CostOfDevelopmentServices	1297000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93128000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81757000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	76123000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	64432000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40445000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41267000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	262769000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	219437000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-134055000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-123338000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3060000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	778000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	644000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	644000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1654000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-48000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-133293000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-123252000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	240000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-133533000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-123228000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102663000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102663000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101853000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101853000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-133533000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-123228000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7535000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12758000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-163000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-792000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13550000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-123228000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	533040000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7372000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13550000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-126161000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-136778000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	60180000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	157000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	993000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22266000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7372000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-133533000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-44551000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	645005000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	963000	usd
CY2022Q1	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	8000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	957000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24799000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-133533000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-123228000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10345000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7201000	usd
CY2023Q1	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	7339000	usd
CY2022Q1	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	6949000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-300000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2390000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	22266000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24799000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	644000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	642000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1009000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2449000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	3882000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
CY2023Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	5485000	usd
CY2022Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12349000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13299000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5125000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5937000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3354000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-21882000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1765000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3846000	usd
CY2023Q1	gh	Increase Decrease In Accounts Payable Accrued And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities	13886000	usd
CY2022Q1	gh	Increase Decrease In Accounts Payable Accrued And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities	20931000	usd
CY2023Q1	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-7422000	usd
CY2022Q1	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3106000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4145000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-757000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74441000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28619000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	63252000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	163742000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	228000000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	310000000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12750000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7524000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22700000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	157224000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	110808000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	18000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	18000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	157000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	963000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	993000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	957000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-854000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-163000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-792000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	81766000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	81385000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	141948000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	492288000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	223714000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	573673000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1964000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3940000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8016000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19751000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	223640000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	573604000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	74000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	69000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	223714000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	573673000	usd
CY2022Q4	gh	Number Of Patients NumberOfPatients	20000	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. </span></div>The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	100000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	300000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	19600000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	25000000	usd
CY2023Q1	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	5500000	usd
CY2022Q3	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	5300000	usd
CY2023Q1	gh	Equity Security Fvni Impairment Or Adjustments To Carrying Value EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue	0	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div>The Company is also subject to credit risk from its other receivables and other assets.
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss ContractualReceivablesBeforeAllowanceForCreditLoss	8000000	usd
CY2020Q3	gh	Contractual Receivables Term ContractualReceivablesTerm	P6Y
CY2020Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1000000	usd
CY2021Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1100000	usd
CY2022Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1100000	usd
CY2023Q1	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	4800000	usd
CY2023Q1	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	1100000	usd
CY2022Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	0	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6400000	usd
CY2023Q1	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2022Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2023Q1	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	usd
CY2022Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	usd
CY2023Q1	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	3700000	usd
CY2022Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	4800000	usd
CY2023Q1	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	3700000	usd
CY2022Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2023Q1	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	usd
CY2022Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	usd
CY2022Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2023Q1	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	usd
CY2022Q1	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	usd
CY2023Q1	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2022Q1	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2022Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2023Q1	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	usd
CY2022Q1	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	usd
CY2023Q1	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	3700000	usd
CY2022Q1	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4300000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5400000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3400000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3800000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2023Q1	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	600000	usd
CY2022Q1	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	2100000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17100000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	21200000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3500000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	260981000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	256051000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	97752000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	88131000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163229000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	167920000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	9600000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	6700000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	67320000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	68911000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	69423000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	55788000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	23619000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21878000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30172000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29240000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	190534000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	175817000	usd
CY2023Q1	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	851703000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9257000	usd
CY2023Q1	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	842467000	usd
CY2022Q4	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	904446000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16779000	usd
CY2022Q4	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	887675000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	99537000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	64000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	590849000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	9193000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	690386000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	9257000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	170975000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2958000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	685754000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	13821000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	856729000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	16779000	usd
CY2022Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3900000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3900000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18586000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7539000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11047000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	3290000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	3290000	usd
CY2023Q1	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7539000	usd
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	14337000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18586000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6859000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11727000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6859000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	15017000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2067000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2219000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1670000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1212000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1107000	usd
CY2023Q1	gh	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	2772000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11047000	usd
CY2020Q4	gh	Convertible Debt Hedge Strike Price ConvertibleDebtHedgeStrikePrice	182.60
CY2020Q4	gh	Convertible Debt Hedge Share Price Premium Percentage ConvertibleDebtHedgeSharePricePremiumPercentage	0.75
CY2020Q4	us-gaap	Share Price SharePrice	104.34
CY2020Q4	gh	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges	90000000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	7300000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	6900000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0393
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0393
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	23612000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	33668000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	32655000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	27799000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	24479000	usd
CY2023Q1	gh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	125157000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	267370000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	38894000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	228476000	usd
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20875818	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16249546	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5438296	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3402574	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39749000	usd
CY2023Q1	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	40091	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	30.30
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21049	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.43
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	49055	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	60.60
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	9333892	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3372561	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.08
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	32766000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2091671	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.26
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	32077000	usd
CY2022Q1	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.82
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	36.32
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	39700000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22266000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24799000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-133533000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-133533000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-123228000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-123228000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102663000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102663000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101853000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101853000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18015000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14961000	shares
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Revenues Revenues	128714000	usd
CY2022Q1	us-gaap	Revenues Revenues	96099000	usd

Files In Submission

Name	View Source	Status
gh-20230331_cal.xml	Edgar Link	unprocessable
0001576280-23-000060-index-headers.html	Edgar Link	pending
0001576280-23-000060-index.html	Edgar Link	pending
0001576280-23-000060.txt	Edgar Link	pending
0001576280-23-000060-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gh-03312023x10qxex311.htm	Edgar Link	pending
gh-03312023x10qxex312.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gh-03312023x10qxex313.htm	Edgar Link	pending
gh-03312023x10qxex321.htm	Edgar Link	pending
gh-03312023x10qxex322.htm	Edgar Link	pending
gh-03312023x10qxex323.htm	Edgar Link	pending
gh-20230331.htm	Edgar Link	pending
gh-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
gh-20230331_def.xml	Edgar Link	unprocessable
gh-20230331_pre.xml	Edgar Link	unprocessable
gh-20230331_lab.xml	Edgar Link	unprocessable
gh-20230331_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2023 Q2 Form 10-Q Financial Statement

#000157628023000060 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2023 Q2 Form 10-Q Financial Statement

#000157628023000060 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh